Healthcare & Life Sciences
Padlock Therapeutics
France
acquiredacquired
acquired
Stage
2
Investors
About
Padlock Therapeutics develops medicines targeting protein-arginine deiminases (PADs), enzymes involved in autoantigen generation, inflammation, and immune complexes in autoimmune diseases.
Explore Padlock Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.